Cells of the immune system are auxotrophs for most amino acids, including several nonessential ones. Arginine and tryptophan are used within the regulatory immune networks to control proliferation and function through pathways that actively deplete the amino acid from the microenvironment or that create regulatory molecules such as nitric oxide or kynurenines. How immune cells integrate information about essential amino acid supplies and then transfer these signals to growth and activation pathways remains unclear but has potential for pathway discovery about amino sensing. In applied research, strategies to harness amino acid auxotrophy so as to block cancerous lymphocyte growth have been attempted for decades with limited success. Emerging insights about amino acid metabolism may lead to new strategies in clinical medicine whereby both amino acid auxotrophy and the immunoregulatory pathways controlled by amino acids can be manipulated.
Humans and most mammals long ago ceased producing 9 of the 20 amino acids needed for protein biosynthesis. These are instead acquired from the diet and microbiota. Most cells of the immune system (with a few notable exceptions discussed herein) have additional requirements for nonessential amino acids such as glutamine and asparagine. The need for an external supply of a nutrient is called auxotrophy. Amino acid auxotrophy has evolved to become an immunoregulatory control point that shapes immune responses, controls the production of antimicrobial effectors and their tissue damage, and tempers T cell responses through a variety of mechanisms including amino acid starvation.
Early investigations of amino acid auxotrophy in immune responses led to the discovery that macrophages block tumor growth through the consumption of arginine, or use arginine to make an antitumor molecule, later discovered to be nitric oxide (NO) [1] [2] [3] [4] [5] [6] . Thus, by the late 1970s, two features of the biology of the arginine immunoregulatory system had been discovered with limited knowledge about the proteins and pathways involved. Thirty years later, arginine metabolism through the depletion and NO pathways remains an area of interest. In addition, tryptophan metabolism has emerged as an important immunological control mechanism 7 . I will concentrate here on arginine and tryptophan, and also note new areas of study relating to amino acid auxotrophy, including its exploitation in clinical medicine.
Regulated amino acid metabolism
Over the course of immune system evolution, two primary amino acid metabolic regulatory nodes were selected: arginine and tryptophan. The regulated enzymes that metabolize arginine are inducible nitric oxide synthase (iNOS), arginase-1 and arginase-2 (Arg1 and Arg2, respectively) ( Fig. 1) . Indoleamine 2,3-dioxygenases (IDO1 and IDO2) are enzymes that metabolize tryptophan. At this point it is important to stress that these are the regulated enzymes closely linked to immunological control mechanisms. This is not to discount other uses of amino acids in protein biosynthesis or in key metabolic pathways. However, it is curious that there seems to be no regulated enzyme systems to destroy or metabolize leucine or threonine, for example, given that these are also essential amino acids. A reasonable model is that nature selected the arginine and tryptophan pathways as sufficient and subsequently refined them into more complex regulatory pathways.
An additional immune-linked amino acid-metabolizing protein is interleukin 4 (IL-4)-inducible 1, IL4i1, encoded by Il4i1 (Fig. 1) . IL4i1 is an amino acid oxidase that is possibly secreted or localized to lysosomes 8, 9 . Little is known about IL4i1, including its precise substrate specificity, although some new work has linked IL4i1 to the promotion of regulatory T cells and aberrant T cells responses in cancer 8, 10 or the suppression of human T H 17 cells 11 . IL4i1 is interesting because it is closely related at the sequence level to l-amino acid oxidases found in high abundance in snake venoms 12 , making its potential immunological roles intriguing. At this point, Il4i1-deficient mice have yet to be described. As IL4i1 is the only known secreted l-amino acid oxidase encoded in the human or mouse genomes, it seems likely that it has a key role in one or more immunological processes that await evaluation.
Arginine metabolism in macrophages Activated macrophages (and lymphocytes) import arginine through cation transporters (especially the inducible SLC7A2 transporter) 13 . A substantial literature has accumulated about arginine metabolism in macrophages over the last three decades 14 . However, the immunespecific tasks requiring arginine are often misunderstood. In part, misconceptions about arginine use in activated macrophages have arisen because of efforts to promote dualistic models of arginine metabolism based around NO-producing M1 macrophages versus arginine-hydrolyzing M2 macrophages 15 and problems in translating findings in mouse systems to human macrophages 16 .
Macrophage activation (or polarization) is a complex area of research because there are no straightforward means to precisely define how individual macrophages have been stimulated in complex immune microenvironments. In vivo, macrophage activation involves at least three intertwined pathways that establish the final activation state: developmental pathways that lead bone marrow-derived inflammatory monocytes to become macrophages within tissues, tissue microenvironmental cues that vary across organs and inflammatory environments, and the influence of polarizing cytokines or other molecules 17 . Most researchers are familiar with the latter 'polarization' pathways, as bone marrow-derived macrophages (BMDMs) or rested peritoneal inflammatory macrophages can be readily and reproducibly M1 or M2 polarized with interferon-γ (IFN-γ) and Tolllike receptor (TLR) agonists or with IL-4 and IL-13, respectively 18 . The experimental polarization of BMDMs is a limited reflection of what happens in vivo, as the culture conditions either are artificial or fail to replicate the tissue microenvironment. However, the in vitro evaluation of changes in activation brought about by the different cytokine milieus allowed different groups to establish the concept of polarization linked to function and the idea that different polarization conditions are associated with differences in protein expression [19] [20] [21] [22] [23] [24] . Dualistic models of macrophage activation were proposed on the basis of inflammation versus wound healing in different mouse backgrounds 25 . Over time, the means to describe polarization markers, functional consequences of polarization and the association of polarization with arginine metabolism soon evolved into a hydra of terminological confusion that is still being incrementally addressed by researchers in the field 18, 26 .
In M2-dominated immunity (seen in worm infections, asthma and tissue repair, for example), macrophages make ornithine but very little or no NO. M2 macrophages have high expression of Arg1 but negligible expression of iNOS, which is regulated by IFN-γ. Deletion of Arg1 is lethal, as Arg1 has an essential role in the urea cycle. Another arginase isoform, Arg2, is mitochondrial, and deletion of Arg2 has more limited phenotypic effect 27 . The influence of Arg2 on immunity and arginine metabolism has yet to be fully explored. However, Arg2 should not be ignored, as the reactions performed by Arg1 and Arg2 are identical. For example, Arg2 inhibits NO output in Helicobacter pylori infections 28 . Therefore, experimental attribution of ornithine production and NO regulation must account for the activity of both enzymes. How Arg2 expression is regulated remains a gap in current knowledge.
Functions of Arg1 in M2 macrophages
Arg1 expression in M2 conditions is controlled by many factors, but the major axis is mediated by IL-4 and IL-13, which activate the transcription factor STAT6 (Fig. 2a) 29 . STAT6 binds to an enhancer in the Arg1 locus and cooperates with other transcription factors such as C/EBPβ 30, 31 . In this setting, STAT6 enforces an >100-fold increase in Arg1 expression. Other factors also increase Arg1 expression, including IL-10-mediated increases in the expression of the IL-4 receptor 32 . PPAR transcription factors also regulate Arg1 expression in M2 macrophages 33 . The PPAR pathway is likely to be a central means to enforce M2-like Arg1 + phenotypes on tissue-resident macrophages, such as adipose macrophages, which use the M2 pathway to balance inflammation in fat tissue and whole-organism metabolism 34 .
A central question in understanding the links between amino acid metabolism and immunity is, Why do M2-activated macrophages make a protein that destroys arginine? A key advance toward answering this question was the development of macrophage-specific Arg1-deficient (Arg1 ∆M ) mice 35 . Using these animals to probe M2 infections, we found that Arg1 has organ-specific effects in controlling T cell proliferation 36, 37 . For example, Arg1 ∆M mice infected with Schistosoma mansoni had a lethal T cell-associated immunopathologic non-resolving inflammatory response to worm eggs in the liver 36 or in the gut 38 . In this model, which replicates many features of the human disease bilharzia, macrophages encircle toxic worm eggs, walling them off from the liver parenchyma (Fig. 2b) . Activated T cells making IL-4 and IL-13, together with recruited eosinophils, drive a potent T H 2 response necessary to kill and dispose of the egg 39 . The T H 2 response enforces M2 polarization in local inflammatory macrophages, which express large amounts of Arg1. A popular hypothesis was that M2 Arg1 + macrophages would produce ornithine, which can contribute to collagen synthesis 40 . However, schistosome-infected Arg1 ∆M mice have increased liver fibrosis and collagen deposition, establishing that macrophage Arg1 is not essential for the production of collagen 36 .
Another finding from the schistosome model was that the effects of macrophage-specific Arg1 in restricting T cell proliferation are confined to the liver and are not found in the lungs when worm eggs were artificially lodged in the lung parenchyma 37 . One interpretation of this finding relates to the relative perfusion rates of the two organs. Blood flow through the lung provides sufficient arginine that any effects of macrophage Arg1 in hydrolyzing arginine are not seen, whereas in the liver, the lower rate of blood flow combined with the high expression of Arg1 in hepatocytes (as part of the urea cycle) results in a higher relative rate of arginine hydrolysis than occurs in the lung. Thus activated T cells drawn to the liver in response to worm eggs encounter an arginine-poor microenvironment and cease proliferating, helping to dampen the inflammatory response to the toxic eggs and eventually reduce and resolve the granulomatous inflammatory response. By contrast, the removal of Arg1 in macrophages alone (but not hepatocytes) causes a lethal non-resolving inflammation. Confirmation that macrophages locally deplete arginine from T cells Figure 1 Regulated amino acid-metabolizing enzymes in immunity. Shown are structures and reaction mechanisms of iNOS, IDO1 and Arg1 derived from deposited coordinates in the PDB (pdb.org). The structure of IDO2 has not been reported but is expected to be similar to that of IDO1. The structure of Arg2 is similar to that of Arg1 (ref. 109 ). The primary sequence structure of mammalian IL4i1 is conserved compared to snake venom l-amino acid oxidases 110 .
will require means to measure the rate of arginine hydrolysis in the organs of living animals. Beyond the obvious technological challenge of such an experiment, these data raise the key question of exactly how T cells detect how much arginine is necessary for their growth and function. A considerable literature exists on the consequences of arginine deprivation in T cells, and low arginine potentially regulates T cell proliferation and function in vivo [41] [42] [43] . However, isolation and phenotypic characterization of T cells from arginine-deprived immune microenvironments will be essential to trace the decisionmaking process that T cells use to decide whether there is sufficient arginine available for proliferation and function. The use of the Arg1 ∆M mice has also revealed other important aspects of macrophage-specific Arg1 expression. For example, Arg1 is required for direct antiworm activity of macrophages (Fig. 2c) . In one experimental setting using Heligmosomoides polygyrus, macrophages encased worms that had been previously coated with worm-specific antibodies and blocked their motility 44 . However, macrophages from Arg1 ∆M mice did not inhibit worm movement. Although the mechanism involved remains unclear, ornithine production from macrophages was required. The involvement of M2 macrophages in direct antiworm functions is consistent with evolution of the M2 pathway to fight helminth infections and at the same time suppress excessive T cell responses.
Ornithine production and Arg1 have long been associated with wounding 45 . In one study in which Arg1 ∆M mice were used in a model of wound repair, macrophage Arg1 was important to the rate of healing, although an excessive T cell response was not observed 46 . These data argue that M2-linked Arg1 has multiple roles in immunity, but the most consistent theme concerns the ability of macrophage M2 macrophages to deprive other cells of arginine.
Arginine metabolism in M1-type activated macrophages A key function of M1-type macrophages is NO production from arginine and oxygen catalyzed by iNOS 47 . NO is directly toxic to many microbes, and especially intracellular pathogens, in addition to its myriad signaling and regulatory roles 47, 48 . Upon activation by IFN-γ and microbial products in a closed experimental system in vitro, M1-type macrophages import, by means of the regulated SLC7A2 transporter 13, 49 , all available arginine and create NO 50 . These data suggest that M1 macrophages do not conserve arginine once provoked to make NO. As the final fate of the vast majority of inflammatory monocyte-derived macrophages is death, NO-producing M1 macrophages seem to be on a suicide mission to counter microbial infection. Consistent with this model, NO poisons the respiratory chain of mitochondria, forcing activated macrophages to import glucose and create energy from a Warburg-type metabolism 51 . A fundamental question in myeloid cell biology concerns the final fates of inflammatory monocytes that are activated to make NO and consume glucose: do they all die? Is the process reversible in a fraction of cells, and, if so, how do surviving macrophages rebuild their mitochondria?
A problem for the host is the cytotoxicity of NO to host tissues, prompting a need to temper NO output. Arginases are the chief means that macrophages use to suppress NO production once the decision to activate iNOS is made. Arg1 and iNOS, when expressed in the same cell, compete with each other for arginine 52 . Mycobacterially infected macrophages, which would be classified as on the M1 part of the polarization spectrum by virtue of the many TLR-and NLRactivating ligands from the bacteria, induce expression of Arg1 (and probably Arg2) but through a pathway completely independent of the STAT6-mediated M2 pathway (Fig. 2a) . Instead, TLR signaling induces the cytokines IL-6, G-CSF and IL-10, which signal through an autocrine-paracrine route to their cognate receptors, thereby activating STAT3 to upregulate Arg1 (ref. 53 ). M1 macrophages therefore coexpress iNOS and Arg1, a concept diametrically opposed to the dualistic model whereby macrophages express iNOS or Arg1 (ref. 54) . Deletion of macrophage Arg1 causes increased NO output and provides an advantage to the host in terms of controlling experimental Mycobacterium tuberculosis (Mtb) infection (Fig. 2d) 35 . However, Arg1 (and probably Arg2) also regulate NO output by controlling how much iNOS protein is made by macrophages. Arg1 can block translation of the iNOS mRNA 55, 56 . Translating the relative Arg1-dependent effect of arginine competition as compared to other NO regulation pathways to in vivo settings is likely to require single-cell techniques in which each individual parameter can be quantified. (STAT6 and STAT3 ). In addition, other pathways modulate the STAT3 and STAT6 pathways, as for IL-10-mediated increases in IL-4Rα expression 32 , or act independently of the main pathways, as with the hypoxia, lactate and adenosine pathways [111] [112] [113] 
Expression of Arg1 in M1-polarized infections also has a key immunoregulatory role in blocking T cell proliferation in Mtb infection. To separate this pathway from Arg1's regulatory effect on NO output required the use of a unique Mtb model 57 . Although this is seemingly counterintuitive, Mtb infection of iNOS-deficient mice through the ear dermis induces a limited granulomatous reaction in the lung following the transit of Mtb bacilli or bacterially-infected cells through the lymph 57 . The dermal infection model allows the dissection of iNOS-independent modes of immunity to Mtb. However, in the absence of iNOS, Arg1 expression was increased in granuloma macrophages, raising the question of its function in this setting (where NO does not require tempering) 58 . To determine the reason for the increased Arg1 expression, mice lacking both iNOS and macrophage Arg1 were infected via the ear dermis. The outcome was a lethal T cell-associated immunopathological reaction in the lung 58 . Thus, macrophage Arg1 was required, as in the M2-dominated schistosome egg model, to suppress T cell proliferation. Macrophage Arg1 plays two essential and linked roles in immune responses: tempering NO output and/or T cell proliferation.
Regeneration of arginine in immune cells
Activated T cells and myeloid cells import substantial amounts of arginine to sustain growth or to use for NO and ornithine production. Are immune cells then truly arginine auxotrophs? Answering this question revealed unexpected complexity in how arginine is metabolized in immune responses, in contrast to the metabolism of arginine in the liver as part of the urea cycle (Fig. 3) . The urea cycle eliminates excess nitrogen, especially excess ammonia, which has differential toxicity to different cells. The urea cycle begins with the condensation, within mitochondria, of ammonia with CO 2 to carbamoyl phosphate, which then donates its carbamoyl group to ornithine to form citrulline. Through the progressive activity of argininosuccinate synthase (ASS1), argininosuccinate lyase (ASL) and Arg1, arginine is created and then destroyed to make urea and ornithine. Urea is excreted, thus ridding the body of the excess nitrogen. Carbamoyl phosphate synthase is not expressed in immune cells. However, ASS1 and ASL are expressed in immune cells, and ASS1 is regulated by TLR signaling 50 . The function of ASS1 and ASL was suspected to use the product of NO biosynthesis, citrulline, to recreate arginine via sequential energy-dependent condensation and lyase reactions 40, 59 . The enzymes required for this reaction (in macrophages) are iNOS, ASS1 and ASL, which presents a conundrum: why do immune cells import every available molecule of arginine if they can make their own? When we used heavy-atom tracing of arginine metabolism in activated NO-producing macrophages, we found that citrulline was exported into the extracellular space 50 -presenting a second conundrum: how can the ASS1-ASL reaction occur if there is no substrate? To solve this problem, we used macrophages lacking full ASS1 activity and manipulated the conditions in which NO was made. When arginine was depleted from the medium and converted to NO, citrulline was reimported and converted through the action of ASS1 and ASL into arginine, providing fuel for more NO production 50 .
Thus, activated macrophages import any available arginine for NO biosynthesis. When arginine becomes limited, citrulline is imported to sustain NO output (Fig. 3) . Consistent with this idea, mice lacking ASS1 in hematopoietic cells were lethally infected with Mtb, arguing for an essential role of the ASS1-ASL-mediated arginine regeneration system in infection immunity 50 . Recent experiments manipulating the amounts of arginine and citrulline in the medium revealed that when M1 macrophages produce NO from citrulline using the arginine regeneration pathway, Arg1 is no longer capable of blocking NO production 60 . These and other data argue that activated macrophages compartmentalize arginine metabolism in some way, possibly through subcellular partitioning of the key enzymes. If so, new cell biological principles could emerge from analysis of the flux of arginine and its products inside and outside cells.
A new twist in the story of arginine regeneration involves the way that M1 macrophages alter their Krebs cycle. Glutamine and glucose tracing showed that M1 macrophages use a Krebs cycle interrupted at the point where citrate is converted to α-ketoglutarate 61 . Once activated, M1 macrophages use anaplerosis reactions ('filling up') to feed metabolites into the segmented Krebs cycle, among them fumarate generated from the lyase reaction of ASL that breaks argininosuccinate into fumarate and arginine (Fig. 3) . NO, arginine and citrulline metabolism are connected to the incomplete Krebs cycle in cells in which mitochondria are unable to make ATP (as a result of NO poisoning) 51, 61 . A limitation of this study was the use of a single time point and the failure to recognize that citrulline is exported and then reimported, increasing the complexity and dynamism of the system.
Tryptophan metabolism and IDO proteins
Like arginine metabolism, tryptophan degradation contributes to immunity through substrate depletion, product supply, or both working together. Three enzymes degrade tryptophan-IDO1, IDO2 and tryptophan dioxygenase (TDO, a liver-specific enzyme)-and each has been implicated in numerous immune responses 7, 62, 63 . The products of the tryptophan degradation pathway, kynurenines and their metabolites, have wide physiological effects. Kynurenines appears to regulate T cells through binding to the aryl hydrocarbon receptor. The physiology of kynurenine metabolite production and their effects is a complex field, and the reader is referred to comprehensive reviews 64, 65 . Kim Caesar/Nature Publishing Group Figure 3 Arginine regeneration and the anaplerotic Krebs 'cycle' in M1 macrophages. Key regulatory events in the links between the pathways include the supply of citrulline as a substrate, the role of NO in blocking mitochondrial respiration, the expression of the key enzymes and the flux through both pathways at a given time 50, 51, 61 . Many features of this reaction cycle remain to be uncovered.
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The IDO1 pathway of tryptophan degradation has received the most attention because the expression of IDO1, like that of iNOS, is controlled by IFN-γ. Several reports have suggested that IDO1 is immunosuppressive because myeloid cells expressing IDO1 import and degrade tryptophan, depleting local supplies of the amino acid and producing kynurenines. The physiology of tryptophan depletion versus product generation remains debatable 66 . The notion that IDO1 is immunosuppressive has propelled the idea that IDO inhibitors such as 1-methyltryptophan (1-MT) could be useful in overcoming local immunosuppression, such as is found in many cancers. Several problems complicate current research into the tryptophan pathway. First, IDO1 and IDO2 are encoded by linked genes (Ido1 and Ido2) arranged in a head-to-tail orientation. The genes' apposition prevents the generation of an efficient meiotic cross to create mice lacking both IDO1 and IDO2. Therefore, results from the available IDO1-or IDO2-deficient mice need to account for the activity of the other protein. Second, commercially available antibody reagents against IDO1 lack specificity (ref. 67 and our unpublished data), and as yet there are no reporter mice that can faithfully track the expression of IDO1 or IDO2 in vivo. Finally, the commonly used IDO inhibitor 1-MT has been shown to be contaminated with tryptophan 68 or to induce IDO1 (ref. 69 ). 1-MT is often used experimentally to 'rescue' immunosuppressive effects of IDO + cells that are considered to deplete local environments of tryptophan: therefore, if 1-MT has sufficient tryptophan as a contaminant, then rescue of growth or function attributed to IDO inhibition may also have a contribution from the supply of tryptophan. A related issue concerns compounds similar to 1-MT that are IDO inhibitors and also inhibit the necroptotic kinase RIPK1 through an entirely different mechanism 70, 71 . Researchers working on necroptosis have begun to systematically appraise more specific RIPK1 inhibitors that appear to have lower activity against IDO proteins. Nevertheless, the specificity of anti-IDO drugs would be best systematically tested by comparing cells from Ripk1 −/− mice to those cells from lacking both IDO proteins to truly establish their on-target range.
One of the key reports in understanding how IDO1 suppresses T cell growth showed that activated T cells sense tryptophan depletion by IDO1 + myeloid cells via the GCN2 pathway, which leads to growth arrest 72, 73 . In the absence of GCN2 in CD8 + T cells, the tryptophansensing mechanism was absent, and T cells entered the cell cycle even when tryptophan was limiting. However, GCN2 is not required for CD4 + T cell-mediated amino acid sensing 74 . Furthermore, neither the GCN2-nor the IDO1-deficient mice have been reported to manifest any type of autoimmunity, and loss of IDO1 has a modest effect on the outcomes of genetically driven lung cancer, but a substantial effect on the outcomes of graft-versus-host response and checkpoint inhibitor efficacy [75] [76] [77] . It remains to be determined whether the phenotypes in the IDO1-deficient mice are mediated by tryptophan catabolism or by other pathways. Taking these results together, the GCN2-IDO1 connection is replete with unresolved mechanistic links to amino acid auxotrophy. The aforementioned issues with 1-MT, antibody specificity and interpretation of the phenotypes of singly IDO-deficient cells raise the specter that much research on the IDO pathway may need to be reevaluated with defined and validated reagents.
Key roles of glutamine in immunity
Glutamine is the most abundant circulating amino acid in the body and is an integral requirement for normal metabolism 78 . Yet antigen-stimulated T cells have an obligatory requirement not just for glutamine but for large quantities of it, which need to exceed a concentration threshold for effective proliferation 79 . TCR stimulation increases the activity of amino acid transporters, which import glutamine (ASCT2, encoded by Slc1a5) and leucine (SLC7A5), as well as the aforementioned cation transporters 80, 81 . Although it is straightforward to accept that proliferating T cells need a lot of amino acids, the selectivity for glutamine is perplexing, especially as proliferating T cells convert to glycolytic metabolism to generate ATP 82 . Perhaps T cells use glutamine in anaplerotic sustenance of Krebs cycle components? Glutamine is required for mTOR activation and stimulation of the anabolic growth machinery needed for division and conversion into T H 1 and T H 17 cells, but not T reg or T H 2 cells, but glutamine starvation propels CD4 + cells toward a T reg cell-like phenotype 83 . This model correlates with data showing that the T cell-specific deletion of mTOR results in a default T reg cell-like phenotype 84 . At this point, however, the challenge will be to link the observations about glutamine metabolism in T cells with the specific biochemistry of T cell subsets.
Another glutamine paradox relates to macrophages. Glutamine is essential for the development of M2 macrophages, as measured by signature gene expression. Glutamine feeds the supply of UDP-GlcNac and subsequent N-linked glycolysis of the M2 secretory protein pool 61 . Glutamine deprivation of IL-4-polarized M2 macrophages blunts the expression signature M2 genes. How this occurs is unknown, but it suggests a connection between the transcriptional machinery needed for M2 polarization and glutamine. By contrast, glutamine deprivation does not affect M1 signature genes, NO production or viability 61 . How the selective differences between M1 and M2 macrophages arise in terms of glutamine metabolism is sure to be important in establishing the signals controlling the polarization of macrophages in vivo.
How do immune cells sense essential amino acids?
The most basic requirement for amino acids is to build proteins. How do cells determine what amounts of amino acids are available for growth and function? At this point it is worth considering modes of cell division and their potential amino acid requirements. Some types of cells divide rarely, if at all (for example, neurons in adults), whereas others have a regimented division cycle to replace lost cells (for example, epithelia). Unabated cell division with a shortened G1 phase of the cell cycle occurs in embryonic stem cells, which divide rapidly to create body mass. In the immune system, another mode of cell division is used by activated lymphocytes emerging from quiescence after antigen stimulation, which create hundreds of copies of themselves to fight infection-after which a fraction enter memory programs while the unneeded cells die. The TORC1 pathway is closely tied to amino acid sensing, according to studies predominantly performed on transformed cells like HeLa 85 . In these systems, TORC1 signaling integrates signals from inside and outside the cell concerning how much amino acids are available. How this works is unclear, as TORC1-associated complexes such as the 'Ragulator' have been implicated in amino acid sensing but have yet to be definitively shown to be 'sensors' 86 . Recently, a lysosomal transporter called SLC38A9 was implicated in amino acid activation of TORC1, but again through an unknown mechanism 87, 88 . Although TORC1 signaling is linked to amino acid availability in transformed cells, it is likely that these links are far more complex in the immune system, where amino acid auxotrophy is so crucial for cell cycle decisions.
Perhaps a clearer way to think about mTOR and TORC1 signaling is to consider their roles in cell growth. TORC1 is required for the emergence of T cells from quiescence and required for the proliferation of thymic T reg cells; this is because TORC1 signals the accumulation of biomass required to generate daughter cells 89, 90 . By contrast, mTOR npg p e r s p e c t i v e nature immunology VOLUME 17 NUMBER 2 FEBRUARY 2016 1 3 7
is dispensable for T cell development 91 92 , and controls macrophage polarization 93 . In the latter case, TORC1 is needed for macrophages to become M1 polarized, but why? It is likely that the answer lies in the amount of biomass (rather than materials for cell division) needed to combat intracellular pathogens, perform antigen presentation and create a robust secretory function, all anabolic activities dependent on TORC1. However, it is unclear whether any of the above examples are tied to direct amino acid sensing. Indeed, in the case of M1 macrophages consuming arginine to make NO, there is no apparent sensing system for tempering arginine consumption as M1 macrophages import all available arginine and oxidize or hydrolyze it until they exhaust the external supply 50 . In summary, the mechanistic basic of amino acid sensing by immune cells remains an open area of research.
Clinical exploitation of amino acid auxotrophy
Early work on the metabolic requirements of transformed cells demonstrated cell type dependence for asparagine 94 . The mechanism of asparagine auxotrophy in cancer cells has generally been assumed to involve mutation, silencing or deletion of the gene encoding the enzyme that converts glutamine to asparagine (asparagine synthase, ASNS, encoded by ASNS) 95, 96 . However, the precise mechanisms involved in asparagine metabolism in cancer remain unresolved. Nevertheless, asparagine auxotrophy is the basis for the administration of bacterial asparaginases in the 'induction' phase of chemotherapy for acute lymphoblastic leukemia (ALL) 97 . ASNases are administered systemically with the rationale of depriving leukemic cells of asparagine and weakening their ability to survive chemotherapy (Fig. 4) . ASNase treatment is now the standard of care for ALL 97 . However, ASNase therapy comes with two penalties. First, ASNases are bacterial and elicit (in some patients) neutralizing antibodies, voiding the efficiency of subsequent ASNase therapy. Second, some ALL patients develop life-threatening allergic responses to ASNases 98 . Thus, a principal limitation of using microbial enzymes to degrade amino acids will be host responses to the foreign protein (Fig. 4) . Cancerous cells are also arginine auxotrophs. To exploit this property, another microbial enzyme, arginine deiminase (ADI) from mycoplasma, has been PEGylated to improve its in vivo pharmacodynamics. ADI is currently being tested in hepatocellular carcinoma and a wide range of other tumors. It will be of considerable interest to determine the extent of anti-ADI host immunity and dose-limiting toxicities.
A tactic for bypassing the host response to microbial amino aciddegrading enzymes is to use human enzymes instead. In this regard, efforts have been made to create a version of Arg1 suitable for injection 99 (Fig. 4) . Although human enzyme formulations should at least partially avoid host responses, a different complication is whether the enzymes will function efficiently in the extracellular milieu as opposed to in an intracellular environment where substrate concentrations are high and enzyme kinetics optimized. The performance of human enzymes, in terms of degradative activity versus pharmacologic properties, in whole animals must be carefully determined. A strong rationale exists to pursue this approach for Arg1, because it can be disgorged from myeloid cells to locally deplete arginine 100, 101 . The fundamental question is whether human cytoplasmic enzymes are sufficiently powerful to limit essential amino acids in cancer therapy.
Activated myeloid cells are immunoregulatory, in that they use amino acid degradation to deprive neighboring cells of essential amino acids. Although degradation of essential amino acids by myeloid cells is a key evolutionary adaptation to prevent host tissue damage, it is also thought to be a barrier to natural and enforced T cell activity against malignant cells because of the potent immunoregulatory activity of enzymes such as Arg1 (ref. 102) . Therefore, the therapeutic usefulness of approaches such as checkpoint blockade must overcome the endogenous immunosuppressive microenvironments rich in myeloid cells expressing enzymes such as Arg1, Arg2, iNOS and IDO. Two branches of clinical development have emerged to block arginases or IDO proteins (Fig. 4) . As noted previously, many questions surround the biology of IDO proteins in cancer and the range and purity of 1-MT.
Perspective
Although substantial advances have been made in understanding regulated amino acid metabolism in immunity, key questions remain. For example, the concept of amino acid starvation leading to a 'spreading' regulatory environment, coined infectious tolerance, has yet to be confirmed by using genetic approaches to manipulate a key essential amino acid 74, 103 . Although we have a platform of knowledge to link macrophage-mediated arginine starvation to the inhibition of T cell proliferation, whether and how the pathway enforces T reg development and function, and its significance to immune responses, remain major npg p e r s p e c t i v e questions. A second aspect of amino acid auxotrophy in immunity that deserves greater evaluation concerns intracellular pathogens that are themselves amino acid auxotrophs (for example, Chlamydia requires host tryptophan 104 ) or express their own amino acid-degrading enzymes (for example, Leishmania has its own arginase 105 ) infecting macrophages that also require exogenous amino acids. Perhaps amino acid competition forms an integral part of the 'macrophage paradox' whereby the cells needed to kill pathogens are also their safe harbor 106 . An opportunity for the field is the ability to mix and match mutant macrophages with mutant pathogens: for example, what would be the outcome if arginase-deficient Leishmania infect Arg1-deficient macrophages? A third question concerns the influence of non-immune cells in microenvironments enforcing amino acid depletion. For example, expression of Arg2 in neuroblastomas is thought to contribute to evasion of immune recognition 107 . However, at the same time, many tumor types are themselves amino acid auxotrophs 108 . Therefore, the complexity of inflammatory microenvironments such as in cancer should yield to new techniques. An impediment to such work, however, is the difficulty of precisely measuring amino acid concentrations in the microenvironment, inside and outside cells, and in living animals.
